Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $203.27, for a total value of $4,065,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Illumina, Inc. (NASDAQ:ILMN) traded down 0.39% on Friday, reaching $207.42. The company had a trading volume of 207,326 shares. The firm has a market capitalization of $30.28 billion, a PE ratio of 41.62 and a beta of 0.76. The stock has a 50 day moving average of $204.12 and a 200 day moving average of $185.47. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $214.34.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14. The business had revenue of $662.00 million for the quarter, compared to the consensus estimate of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $0.86 EPS. On average, analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Illumina, Inc. (ILMN) Director Jay T. Flatley Sells 20,000 Shares” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/2957855/illumina-inc-ilmn-director-jay-t-flatley-sells-20000-shares.html.
A number of equities research analysts have issued reports on ILMN shares. Deutsche Bank AG set a $175.00 price target on Illumina and gave the company a “hold” rating in a research report on Friday, July 28th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and increased their price target for the company from $170.00 to $215.00 in a research report on Monday, August 7th. Morgan Stanley reaffirmed an “underweight” rating and issued a $122.00 price target (up previously from $115.00) on shares of Illumina in a research report on Monday, July 10th. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price target on the stock. in a research report on Wednesday, June 21st. Finally, Barclays PLC reaffirmed a “hold” rating and issued a $150.00 price target on shares of Illumina in a research report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $190.50.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Citizens Bank & Trust Co. lifted its holdings in shares of Illumina by 0.4% in the 2nd quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock worth $536,000 after purchasing an additional 12 shares during the last quarter. Patten Group Inc. lifted its holdings in shares of Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after purchasing an additional 25 shares during the last quarter. Puzo Michael J lifted its holdings in shares of Illumina by 0.4% in the 2nd quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after purchasing an additional 25 shares during the last quarter. Flagship Harbor Advisors LLC lifted its holdings in shares of Illumina by 1.7% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock worth $345,000 after purchasing an additional 35 shares during the last quarter. Finally, Eqis Capital Management Inc. lifted its holdings in shares of Illumina by 0.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock worth $1,200,000 after purchasing an additional 38 shares during the last quarter. 93.32% of the stock is currently owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.